Search
MK-0482
go.drugbank.com/drugs/DB17453InvestigationalMK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Capromorelin
go.drugbank.com/drugs/DB15205InvestigationalCapromorelin is under investigation in clinical trial NCT00527046 (Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults).
Formebolone
go.drugbank.com/drugs/DB01569IllicitInvestigational[A14416] It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act. … Formebolone, a derivative of androstane, is an anabolic androgenic steroid. It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes.
Categories: Testosterone and derivativesHydrocortamate
go.drugbank.com/drugs/DB00769ApprovedGlucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic
Fluocinonide
go.drugbank.com/drugs/DB01047ApprovedInvestigationalA topical glucocorticoid used in the treatment of eczema.
Categories: fluocinonide and antibiotics, Hormones, Hormone Substitutes, and Hormone AntagonistsNabumetone
go.drugbank.com/drugs/DB00461ApprovedNabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568] … [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action.
Categories: Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-SteroidsMolibresib
go.drugbank.com/drugs/DB16239InvestigationalMolibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects
Lutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigational[L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533] … [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate
Reldesemtiv
go.drugbank.com/drugs/DB15256InvestigationalReldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).
Synonyms: CK-2127107Buntanetap
go.drugbank.com/drugs/DB15317InvestigationalBuntanetap (previously known as Posiphen) is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease).